article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Li, MD, Professor of Pathology and Laboratory Medicine, Director of Cancer Genomic Diagnostics. What is CancerVar?

article thumbnail

For bacteria, a small genome means some serious decluttering — even in the ribosome

Scienmag

Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PanOmics: Advancing drug discovery

Drug Discovery World

The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods. phosphorylations or ubiquitinations).

Drugs 52
article thumbnail

Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb On Targeted Protein Degradation

The Pharma Data

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Protein 40
article thumbnail

Sensyne, Oxford University deploy AI to find asthma targets

pharmaphorum

The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

article thumbnail

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

pharmaphorum

It will attempt to validate the software by comparing its findings with clinical data such as brain imaging and genomics analyses to see if it can accurately detect neurocognitive impairments that can’t be found using current tests.

Trials 76